China Consolidates Medical Device Authority Under State Drug Administration
This article was originally published in The Gray Sheet
Executive Summary
Reorganization of China's bureaucratic regime consolidates administrative authority for medical devices in the newly established State Drug Administration (SDA), a move that helps clarify prior ambiguity over the role of the Chinese Ministry of Health in the medical device arena.
You may also be interested in...
QSRs Proposed As Alternatives To "Type Testing" In China and Korea
Chinese officials responsible for medical device regulation in China's State Drug Administration might participate in a proposed quality system regulation training program tentatively slated for late summer.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.